Niagen Bioscience (NAGE) Non-Current Debt (2016)

Niagen Bioscience's (NAGE) quarterly Non-Current Debt came in at $3.3 million in Q1 2016.

Niagen Bioscience (NAGE) Non-Current Debt (2016) Analysis & Trends

Niagen Bioscience (NAGE) has 1 years of Non-Current Debt data on file, last reported at $3.3 million in Q1 2016.

On a quarterly basis, Non-Current Debt changed N/A year-over-year to $3.3 million in Q1 2016; TTM through Jan 2016 was $3.3 million, a N/A change from a year earlier, with the FY2016 full-year figure at $3.3 million, changed N/A from the prior year.
Non-Current Debt for Q1 2016 stood at $3.3 million.
Over the last five years, Non-Current Debt for NAGE reached as high as $3.3 million in Q1 2016 and fell as low as $3.3 million in Q1 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Niagen Bioscience	253.47 Mn	186.92 Mn	19.98 Mn	-

Historic Data

Download Data

Date	Value
Jan 2, 2016	3.35 Mn